TY - JOUR
T1 - Tacrolimus attenuates Th17 cell-mediated allergic skin inflammation in mice
AU - Mirkatouli, Fatemeh Beygom
AU - Tao, Yukiko
AU - Enkhbaatar, Uyanga
AU - Yamanaka, Ryoken
AU - Miura, Kento
AU - Yamasaki, Norimasa
AU - Ogata, Sawako
AU - Hosomi, Naohisa
AU - Mori, Akio
AU - Yasuda, Tomoharu
AU - Matsuda, Masaya
AU - Sannomiya, Yuya
AU - Nabe, Takeshi
AU - Numata, Tomofumi
AU - Sugiura, Kazumitsu
AU - Kitamura, Noriko
AU - Gotoh, Minoru
AU - Kaminuma, Osamu
N1 - Publisher Copyright:
© 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/
PY - 2026/3
Y1 - 2026/3
N2 - Tacrolimus, a topical calcineurin inhibitor, is used to treat atopic dermatitis (AD). AD is classically T helper type (Th) 2-driven, but Th17 cells are implicated in chronic AD, yet its efficacy against Th17-dependent pathology remains unclear. We investigated the effects of tacrolimus using a murine model of Th17-mediated allergic skin inflammation. In CD4+T cells from DO11.10/Rag2−/−mice, which express ovalbumin (OVA)-specific T cell receptor, tacrolimus differentially suppressed stimulation-induced cytokine expression by Th2 cells. At similar concentrations, tacrolimus suppressed Il21, but not Il17a or Il22, expression in Th17 cells. Subcutaneous OVA challenge elicited ear thickening in BALB/c mice after adoptive transfer of Th2 or Th17 cells, with a stronger response in Th17-transferred mice, but less than OVA-immunized controls. Topical tacrolimus reduced Th17-mediated ear swelling, corroborated by histopathology. In Th2-transferred mice, tacrolimus tended to reduce early skin thickening (day 3) but did not affect late responses (day 7). In Th17-transferred mice, tacrolimus significantly reduced allergen-specific T-cell accumulation in OVA-injected skin and tended to reduce Il21 expression, whereas Th2-cell accumulation and cytokine expression were unaffected. Tacrolimus exerts stronger inhibitory effects on Th17- than Th2-driven responses in this model, suggesting that suppression of Th17 pathways may contribute to its therapeutic benefit in AD.
AB - Tacrolimus, a topical calcineurin inhibitor, is used to treat atopic dermatitis (AD). AD is classically T helper type (Th) 2-driven, but Th17 cells are implicated in chronic AD, yet its efficacy against Th17-dependent pathology remains unclear. We investigated the effects of tacrolimus using a murine model of Th17-mediated allergic skin inflammation. In CD4+T cells from DO11.10/Rag2−/−mice, which express ovalbumin (OVA)-specific T cell receptor, tacrolimus differentially suppressed stimulation-induced cytokine expression by Th2 cells. At similar concentrations, tacrolimus suppressed Il21, but not Il17a or Il22, expression in Th17 cells. Subcutaneous OVA challenge elicited ear thickening in BALB/c mice after adoptive transfer of Th2 or Th17 cells, with a stronger response in Th17-transferred mice, but less than OVA-immunized controls. Topical tacrolimus reduced Th17-mediated ear swelling, corroborated by histopathology. In Th2-transferred mice, tacrolimus tended to reduce early skin thickening (day 3) but did not affect late responses (day 7). In Th17-transferred mice, tacrolimus significantly reduced allergen-specific T-cell accumulation in OVA-injected skin and tended to reduce Il21 expression, whereas Th2-cell accumulation and cytokine expression were unaffected. Tacrolimus exerts stronger inhibitory effects on Th17- than Th2-driven responses in this model, suggesting that suppression of Th17 pathways may contribute to its therapeutic benefit in AD.
KW - Atopic dermatitis
KW - DO11.10
KW - IL-21
KW - Tacrolimus
KW - Th17 cells
UR - https://www.scopus.com/pages/publications/105029734195
UR - https://www.scopus.com/pages/publications/105029734195#tab=citedBy
U2 - 10.1016/j.jphs.2026.01.003
DO - 10.1016/j.jphs.2026.01.003
M3 - Article
C2 - 41672639
AN - SCOPUS:105029734195
SN - 1347-8613
VL - 160
SP - 152
EP - 157
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
IS - 3
ER -